Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Health Plans PA | OpenPaye…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy 2026D0057T

    Buprenorphine (Brixadi and Sublocade) for Opioid Use Disorder

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0057T alerts

    Get alerted when Policy 2026D0057T changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Brixadi and Sublocade subcutaneous extended-release buprenorphine injections for moderate to severe opioid use disorder; pain management use is not medically necessary.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyBuprenorphine (Brixadi and Sublocade) for Opioid Use Disorder
    Policy CodePolicy 2026D0057T
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionDocument opioid use disorder treatment, applicable therapy criteria, FDA-labeled dosing, and authorization periods of no more than 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was transferred to a shared template applying to both UnitedHealthcare Commercial and Individual Exchange benefit plans.

    An Application section was added identifying UnitedHealthcare Commercial and Individual Exchange benefit plans.

    The References section was updated with current information and previous policy versions were archived.

    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered drug products addressed
    4Applicable HCPCS drug codes
    12 monthsInitial authorization limit
    12 monthsContinuation authorization limit
    Pain managementExcluded indication

    Coverage Criteria

    Initial Therapy

    Covered when all of the following are met for initial therapy:

    Initial therapy requirements

    • Patient is being treated for opioid use disorder.
    • ONE of the following buprenorphine treatment pathways applies

      • Not currently receiving maintenance buprenorphine

        • Patient is not currently receiving maintenance buprenorphine treatment.
        • Patient has received a test dose of buprenorphine establishing tolerance without precipitated withdrawal.
      • Already treated with buprenorphine

        • Patient is already being treated with buprenorphine.
    • Brixadi or Sublocade dosing is in accordance with FDA-approved labeling.
    • Initial authorization is for no more than 12 months.Initial authorization <= 12 months

    Continuation Therapy

    Covered when all stated continuation requirements are met:

    Continuation therapy requirements

    • Documentation demonstrates a positive clinical response to buprenorphine extended-release therapy.
    • Brixadi or Sublocade dosing is in accordance with FDA-approved labeling.
    • Continuation authorization is for no more than 12 months.Continuation authorization <= 12 months

    Buprenorphine extended-release injection, including Brixadi and Sublocade, is unproven and not medically necessary for pain management.

    Use of buprenorphine extended-release injection for pain management is not medically necessary.

    Applicable Codes

    Applicable Procedure and Drug CodesHCPCS
    J0577Injection, buprenorphine extended-release (Brixadi), less than or equal to 7 days of therapy
    J0578Injection, buprenorphine extended-release (Brixadi), greater than 7 days and up to 28 days of therapy
    Q9991Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg
    Q9992Injection, buprenorphine extended-release (Sublocade), greater than 100 mg
    Applicable Diagnosis CodesICD-10
    F11.20Opioid dependence, uncomplicated
    F11.21Opioid dependence, in remission
    F11.220Opioid dependence with intoxication, uncomplicated
    F11.221Opioid dependence with intoxication delirium
    F11.222Opioid dependence with intoxication with perceptual disturbance
    F11.229Opioid dependence with intoxication, unspecified
    F11.23Opioid dependence with withdrawal
    F11.24Opioid dependence with opioid-induced mood disorder
    F11.250Opioid dependence with opioid-induced psychotic disorder with delusions
    F11.251Opioid dependence with opioid-induced psychotic disorder with hallucinations
    1–10 of 15
    1/2

    Prior Authorization and Coverage Requirements

    Prior Authorization

    Initial Therapy Authorization

    Before starting Brixadi or Sublocade, submit documentation that the patient is being treated for moderate to severe opioid use disorder. For patients not currently receiving maintenance buprenorphine, document a test dose establishing tolerance without precipitated withdrawal; patients already being treated with buprenorphine may also qualify. Confirm dosing follows FDA-approved labeling, and limit initial authorization to no more than 12 months.

    • Document the opioid use disorder diagnosis and treatment plan.
    • Document either current maintenance buprenorphine treatment or a tolerated test dose without precipitated withdrawal.
    • Include the requested product, dose, schedule, and confirmation that dosing is consistent with FDA-approved labeling.
    • Request no more than 12 months of initial authorization.
    Prior Authorization

    Continuation Authorization

    For continuation authorization, submit documentation of a positive clinical response to extended-release buprenorphine therapy, ongoing treatment for opioid use disorder, and continued use of Brixadi or Sublocade in accordance with FDA-approved labeling. Continuation authorization is limited to no more than 12 months.

    Clinical Background

    Brixadi and Sublocade are buprenorphine products administered by subcutaneous injection for the treatment of moderate to severe opioid use disorder.

    Initial Therapy

    Initial Therapy

    For initial therapy, all of the following are required:

    Initial therapy requirements

    • Patient is being treated for opioid use disorder.
    • ONE of the following applies

      • Not currently receiving maintenance buprenorphine

        • Patient is not currently receiving maintenance buprenorphine treatment.
        • Patient has received a test dose of buprenorphine to establish that buprenorphine is tolerated without precipitated withdrawal.
      • Already treated with buprenorphine

    Continuation of Therapy

    Continuation of Therapy

    For continuation therapy, all of the following are required:

    Continuation requirements

    • Documentation of positive clinical response to buprenorphine extended-release therapy.
    • Brixadi or Sublocade dosing is in accordance with FDA-approved labeling.
    • Continuation authorization will be for no more than 12 months.Continuation authorization <= 12 months

    Authorized Site of Care

    Billing Rule

    Use a certified office and pharmacy

    Order and dispense Brixadi and Sublocade through certified healthcare settings and pharmacies in accordance with the applicable REMS program. Brixadi must be dispensed directly to a healthcare provider for administration.

    • Brixadi: the ordering healthcare setting and pharmacy must be certified in the Brixadi REMS.
    • Sublocade: the ordering healthcare setting and pharmacy must be certified in the Sublocade REMS Program and comply with its requirements.
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyBuprenorphine (Brixadi and Sublocade) for Opioid Use Disorder
    Policy CodePolicy 2026D0057T
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionDocument opioid use disorder treatment, applicable therapy criteria, FDA-labeled dosing, and authorization periods of no more than 12 months.
    SourceLink
    On This Page
    Coverage CriteriaApplicable CodesPrior Authorization and Coverage RequirementsClinical BackgroundInitial TherapyContinuation of TherapyAuthorized Site of Care
    • Document positive clinical response to buprenorphine extended-release therapy.
    • Document that treatment for opioid use disorder remains ongoing.
    • Confirm continued FDA-labeled dosing and request no more than 12 months of continuation authorization.
    Documentation Required

    Clinical Eligibility and Response

    Coverage requires documentation that the therapy is being used to treat moderate to severe opioid use disorder and that the patient meets the applicable buprenorphine-treatment pathway. For continuation, the record must show a positive clinical response and continued therapy with appropriately labeled dosing.

    • Document opioid use disorder treatment rather than another indication.
    • For initial therapy, document maintenance buprenorphine status or a tolerated test dose when the patient is not currently receiving maintenance treatment.
    • For continuation, document positive clinical response and ongoing treatment.
    Billing Rule

    Brixadi REMS Compliance

    Brixadi may be obtained and administered only through the restricted Brixadi REMS. Healthcare settings and pharmacies that order or dispense it must be certified, and the product must be dispensed directly to a healthcare provider for administration by a healthcare provider.

    • Verify Brixadi REMS certification for the healthcare setting and pharmacy.
    • Do not dispense Brixadi directly to the patient; direct dispensing to a healthcare provider is required.
    • Maintain compliance with all applicable Brixadi REMS requirements.
    Denial Risk

    Pain Management Use

    Buprenorphine extended-release injection is unproven and not medically necessary for pain management. Requests submitted for pain management rather than treatment of moderate to severe opioid use disorder are at risk for coverage denial.

    • Use Brixadi or Sublocade for the covered opioid use disorder indication, not pain management.
    • Document opioid use disorder treatment and applicable therapy criteria with the authorization request.
    Denial Risk

    Opioid Use Disorder Criteria

    Coverage may be denied when the request does not document treatment of moderate to severe opioid use disorder or does not establish the applicable initial or continuation therapy criteria.

    • No documented opioid use disorder treatment.
    • No documented tolerated buprenorphine test dose when required for a patient not currently receiving maintenance buprenorphine.
    • No documented positive clinical response for continuation authorization.
    Denial Risk

    Non-Label Dosing

    Coverage may be denied when Brixadi or Sublocade is prescribed at a dose or schedule inconsistent with FDA-approved labeling. The requested product and regimen must be documented as label-concordant for both initial and continuation authorization.

    • Confirm the product, dose, and administration schedule are consistent with FDA-approved labeling.
    • Do not submit non-label dosing without documentation that satisfies the policy's applicable criteria.
  1. Patient is already being treated with buprenorphine.
  2. Brixadi or Sublocade dosing is in accordance with FDA-approved labeling.
  3. Initial authorization will be for no more than 12 months.Initial authorization <= 12 months